Together, the matrix metalloproteinases (MMPs) are capable of degrading every component of the extracellular matrix (ECM). Besides degradation of the ECM, MMPs release bioactive molecules from the matrix or cell surface and play important role in tissue repair after injury, development and in a number of pathologies including arthritis and cancer metastasis. Small molecules that inhibit a broad spectrum of metalloproteinases have not proved useful in the treatment of various diseases, probably due to the diverse roles of this large family of enzymes. An alternative therapeutic approach for a number of pathologies is to modulate the expression of specific metalloproteinase genes. Acetylation represents a recently identified covalent protein modification that is strongly implicated in transcriptional regulation. Histones were the first proteins demonstrated to show variable acetylation leading to gene activation. Subsequently, a large number of molecules including structural proteins, intracellular signaling molecules, nuclear membrane receptors and transcription factors were shown to be acetylated. Acetylation, like phosphorylation, is a reversible modification . Acetyl groups are added by a family of histone acetyl transferase enzymes (HATs) and are removed by histone deacetylases (HDACs). Inhibitors of HDACs (HDACi) have potent anti-proliferative and proapoptotic activities in cancer cells and may be used as cancer therapeutics. In this review, we examine the impact of changes in acetylation on the expression of the MMPs and their inhibitors (tissue inhibitors of metalloproteinases, TIMPs). We discuss the suggestion that HDACi may act in a dual fashion: selectively decreasing cancer cell viability and reducing metastatic potential by decreasing stromal cell expression of specific metalloproteinases. Furthermore, we consider the possibility that selective HDACi have a potential as anti-inflammatory agents and in a range of degradative diseases such as arthritis.
ABSTRACT
Together, the matrix metalloproteinases (MMPs) are capable of degrading every component of the extracellular matrix (ECM). Besides degradation of the ECM, MMPs release bioactive molecules from the matrix or cell surface and play important role in tissue repair after injury, development and in a number of pathologies including arthritis and cancer metastasis. Small molecules that inhibit a broad spectrum of metalloproteinases have not proved useful in the treatment of various diseases, probably due to the diverse roles of this large family of enzymes. An alternative therapeutic approach for a number of pathologies is to modulate the expression of specific metalloproteinase genes. Acetylation represents a recently identified covalent protein modification that is strongly implicated in transcriptional regulation. Histones were the first proteins demonstrated to show variable acetylation leading to gene activation. Subsequently, a large number of molecules including structural proteins, intracellular signaling molecules, nuclear membrane receptors and transcription factors were shown to be acetylated. Acetylation, like phosphorylation, is a reversible modification . Acetyl groups are added by a family of histone acetyl transferase enzymes (HATs) and are removed by histone deacetylases (HDACs). Inhibitors of HDACs (HDACi) have potent anti-proliferative and proapoptotic activities in cancer cells and may be used as cancer therapeutics. In this review, we examine the impact of changes in acetylation on the expression of the MMPs and their inhibitors (tissue inhibitors of metalloproteinases, TIMPs). We discuss the suggestion that HDACi may act in a dual fashion: selectively decreasing cancer cell viability and reducing metastatic potential by decreasing stromal cell expression of specific metalloproteinases. Furthermore, we consider the possibility that selective HDACi have a potential as anti-inflammatory agents and in a range of degradative diseases such as arthritis. Chromatin structure and remodeling by histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetylation of the N-terminal tails of histones leads to a loosening of the histone-DNA structure, allowing access of the transcriptional machinery. Furthermore, acetyl groups may associate with and recruit factors containing bromodomains.
INTRODUCTION

Metalloproteinase gene family
The matrix metalloproteinases (MMP) are a family of 23 enzymes in man. These enzymes were originally described as cleaving extracellular matrix (ECM) substrates with a predominant role in ECM homeostasis, but it is now clear that they have much wider functionality. Such functions include: opposing effects on angiogenesis via matrix degradation but also release of angiogenesis inhibitors (via digestion of e.g. plasminogen to generate angiostatin, and type XVIII collagen to generate endostatin); regulation of cell growth via release of cell surface-bound growth factors and receptors, release of growth factors sequestered in the ECM or integrin signalling; regulation of apoptosis via release of death or survival factors; alteration of cell motility by revealing cryptic matrix signals, or cleavage of adhesion molecules; effects on the immune system and host defense; degradation of chemokines (1).
Many MMPs are regulated at the level of transcription by a variety of growth factors, cytokines and chemokines. The promoter structure of several family members has been mapped to some extent, with a promoter proximal AP-1 site as the most obvious shared motif amongst inducible MMPs (2).
Acetylation and chromatin modifications
The role of chromatin modification, and in particular acetylation, is little researched in the metalloproteinase arena. The packaging of eukaryotic DNA into chromatin plays an important role in regulating gene expression. The DNA is wound round a histone octamer consisting of two molecules each of histones H2A, H2B, H3 and H4 to form a nucleosome. This unit is repeated at approximately 200bp intervals with histone H1 associating with the intervening DNA. Nucleosomes are generally repressive to transcription, hindering access of the transcriptional apparatus (3). However, two major mechanisms exist which modulate chromatin structure to allow transcriptional activity: firstly, ATP-dependent nucleosome remodellers such as the Swi/Snf complex (4, 5) ; secondly, the enzymatic modification of histones, via acetylation, methylation and phosphorylation (6) (7) (8) .
Acetylation by histone acetyltransferases (HATs) occurs on specific lysine residues on the N-terminal tails of histone H2A, H2B, H3 and H4. This neutralisation of positive charge leads to a loosening of the histone-DNA structure, allowing access of the transcriptional machinery; furthermore, the acetyl groups may associate with and recruit factors containing bromodomains (Figure 1) (3) . Many transcriptional activators or coactivators have (or recruit) HAT activity, giving a mechanism whereby acetylation can be targeted to specific gene promoters (7, 8) . Conversely, histone deacetylases (HDACs) have also been characterised. Hypoacetylation of histones associates with transcriptional silence, and several transcriptional repressors and co-repressors have been identified which have (or recruit) HDAC activity (9) (10) (11) . Over 80 nonhistone substrates of HATs have also been described, including ~40 sequence-specific transcription factors (e.g. p53, NF-κB, STAT-3 and c-jun (12-16)), and this diversity suggests acetylation represents a biological modification rivaling phosphorylation (8).
Histone deacetylases and inhibitors
There are two families of HDACs, the NAD + -dependent, so-called SIR2 family (sometimes called class III HDACs) and the classical HDAC family. The classical HDACs can be split into three classes (I, II and IV) based on phylogeny (17) . Class I HDACs (HDAC1, 2, 3 and 8) are related to yeast RPD3, and class II HDACs (HDAC4, 5, 6, 7, 9 and 10) are more closely related to yeast HDA1 (9) . HDAC11 alone represents class IV and HDAC11-related proteins have been described in all eukaryotic organisms other than fungi (17) . All classes of the classical HDACs exist in bacteria which lack histone-related proteins, suggesting that the ability to deacetylate histones is not necessarily the main function of these enzymes (17) . However, all 11 mammalian HDACs have histone deacetylase activity and act at least in part as, or associate with, transcriptional repressors although they also appear to have additional functions. Trichostatin A (TSA) and sodium butyrate (NaBy), are HDAC inhibitors (HDACi) (18, 19) with a broad spectrum of activity against class I and II HDACs, but not the SIR2 family. Addition of these reagents to cells should therefore block histone deacetylation and result in increased acetylation of histones on susceptible genes. The prediction would be that this would lead to an increase in gene expression, however, there are many instances of HDACi acting as repressors of gene expression (20-24) and data from microarray studies indicate that an approximately equal number of genes are activated or repressed following HDACi treatment (25-27).
HDACi have potent anti-proliferative and proapoptotic activities in cancer cells and this has led to the development of specific inhibitors for cancer chemotherapy. Such compounds are currently in both preclinical development and clinical trials (28) . For example, MS-275, a synthetic benzamide-containing HDACi is currently undergoing a phase II study in patients with refractory solid tumours and lymphomas; remarkably, considering the possible global gene regulation modulatory effects of these compounds the initial trial of MS-275 showed no dose-limiting toxicity effects, an important observation should more specific HDACi be eventually evaluated for treatment in metalloproteinase-mediated conditions (29) . Interestingly, the anti-epileptic drug, valproic acid, inhibits HDACs, preferentially those in class I. Whilst the anti-epileptic action of valproic acid does not appear to be mediated by its ability to inhibit HDACs, the lack of major toxicity during its long term use demonstrates that inhibition of HDACs (at least class I HDACs) is therapeutically possible (30).
ACETYLATION AND ITS IMPACT UPON METALLOPROTEINASE EXPRESSION
Chromatin modifications and MMP expression
The first report of acetylation impacting upon MMP gene expression was by Pender et al. (31) working with human fetal mucosal mesenchymal cells. In this paper, NaBy and TSA were shown to enhance IL-1β or TNFα induction of MMP-3 and to repress IL-1β or TNFα induction of MMP-1 and MMP-9 both at the mRNA and protein level. No effect of these HDACi was seen on unstimulated levels of any MMP examined, and no effect was seen on MMP-2 or TIMP-1, neither of which was induced by IL-1β or TNFα. From these data, it is likely that the effect of HDACi is on the signaling pathways induced by these proinflammatory cytokines, rather than on the MMP genes themselves, though this is currently unknown. It is interesting that the same HDACi can lead to enhancement or repression of an induced MMP (compare MMP-3 to MMP-1 and -9 above): this might suggest that there are differences in the pathways by which IL-1 or TNFα induce MMP-3 compared to MMP-1 and -9 or that there are subtle differences in the impact of HDACi on e.g. NFκB that are gene specific (see below).
Ailenberg and Silverman (32,33) then described that TSA (across a 6-50ng/ml dose range) could repress MMP2 gene expression at the mRNA level and also the activity of the enzyme in NIH 3T3 cells. Since TSA is a hydroxamate, a moiety that can chelate zinc, they also show that TSA does not directly inhibit MMP-2 activity in the assay used. In this cell line, TSA did not alter expression of either MT1MMP or TIMP2, factors known to be involved in proMMP-2 activation. Interestingly, the human fibrosarcoma cell line HT1080 is much less sensitive to TSA with little effect on MMP2 expression even at 200ng/ml. In line with the dogma, these authors also found that TSA induced apoptosis in the transformed HT1080 line, but not in the 3T3 cells. They therefore suggest that TSA, and other HDACi in development as cancer therapeutics may act in a 'two-pronged' way: selectively decreasing cancer cell viability and reducing metastatic potential by decreasing stromal cell expression of MMP-2.
Similarly, Kaneko et al., (34) demonstrate both reduced invasion through Matrigel, and reduced MMP expression and activity, in response to NaBy. In human liver cancer cell lines, treatment with NaBy (2mM) reduced activity of MMP-2 and MMP-9 and expression of MMP1. The expression of TIMP1 and TIMP2 was unaffected. Since the effect of NaBy on MMP levels was similar to that of interferon-α, the authors speculate on cross-talk or commonality between the signalling pathways activated by these factors. Interestingly, valproic acid was shown to be proapoptotic in LCCaP human prostate cancer cells with concomitant upregulation of TIMP3. These authors also report a similar induction of TIMP3 by TSA (35) .
These papers do not dissect in detail the mechanism(s) by which HDACi impact upon MMP gene expression in terms of the HDAC involved, nor in terms of the number of MMPs affected by an HDACi.
Martens et al (36) consider the induction of the MMP1 gene in T98G human glioblastoma cells by a combination of serum and phorbol ester (phorbol-12-myristate 13-acetate, abbreviated PMA or TPA). This combination gives a potent induction of MMP1 expression at the mRNA level between 90 min and 2 hours with a maximal induction at 4-6 hours. These authors used chromatin immunoprecipitation (ChIP) to identify factors recruited to the MMP1 promoter in this system and examine the kinetics of histone modifications occurring with induction of the gene. Acetylation per se is insufficient to induce MMP1 expression in these cells since TSA had no effect on MMP1 expression despite an increase in local H3 acetylation at the MMP-1 promoter. It appears that upon activation with serum and TPA, c-Jun, c-Fos, TBP, RNAPII and SET9 assemble on the MMP1 promoter and histones at this location are dimethylated (and eventually trimethylated). p300 and RSK2 are then recruited which correlates with an increase in acetylation and phosphorylation of histones at the MMP1 promoter. Finally, Swi/Snf, an ATP-dependent nucleosome remodeling complex is recruiting allowing initiation of transcription.
In a similarly detailed dissection of events at the promoter, Ma et al (37) examined PMA induction of the MMP9 gene in HeLa cells. Increased MMP9 mRNA is apparent by 2 hours of PMA treatment and becomes maximal at 6 hours. An NFκB site, two AP1 sites and an Sp1 site in the MMP9 promoter are all involved in induction. Micrococcal nuclease digestion demonstrates that the MMP9 promoter is in a regular nucleosomal array, and chromatin remodeling is necessary for MMP9 transcription. This latter is elegantly proven by using a Brg1-deficient cell line (SW-13 cells); Brg1 is the ATPase subunit of the Swi/Snf complex. In these cells, MMP9 is not expressed on PMA stimulation, but transfection with Brg1 (but not an ATPase-null mutant) rescued responsiveness of MMP9 expression to PMA. ChIP experiments demonstrated recruitment of AP1 factors, NFκB factors and Sp1 at appropriate time points, and modifications in histone acetylation, phosphorylation and methylation. MTA, a specific protein methyltransferase inhibitor, suppressed PMA-induced MMP9 expression, whilst TSA enhances PMA-induced MMP9 expression. These authors also demonstrated that both HDAC1-and HDAC3-containing complexes occupy the MMP9 promoter in unstimulated HeLa cells, but that these are removed upon stimulation with PMA. This was reinforced by the repressive effects of HDAC1 or HDAC3 (but not HDAC2 or HDAC4) on PMA-induced MMP9.
Both of these papers (36,37) demonstrate a coordinated cascade of cell signaling, histone modifications, nucleosome remodeling and recruitment of transcription factors. This may be cell type, species, or stimulus-specific.
Young et al (38) show that both TSA and NaBy block IL-1/OSM-induced cartilage resorption in an explant model in a dose-dependent manner at the level of both proteoglycan and collagen release. This was accompanied by a reduction in activity and activation of procollagenases in the conditioned medium and a similar reduction in gelatinase activity. In cultured primary chondrocytes, TSA and NaBy repressed the IL-1/OSM-induction of collagenolytic MMPs (MMP-1 and -13) and aggrecanases (ADAMTS-4, ADAMTS-5 and ADAMTS-9). In SW1353 chondrosarcoma cells, the majority of metalloproteinase genes that were robustly induced by the IL-1/OSM combination, were then repressed by the HDACi, these were MMP1, MMP3, MMP7, MMP8, MMP10, MMP12, MMP13 and ADAMTS9.
The basal expression of several metalloproteinase genes was also induced by HDACi, these were MMP17, MMP23, MMP28, ADAMTS15 and ADAMTS17, as well as the inhibitor TIMP2. These data suggest that HDACi impact upon IL-1/OSM signaling to repress induced levels of metalloproteinases and that the basal expression of a number of metalloproteinases are responsive to HDACi. There is no overlap between these groups, which may point to mechanisms/pathways by which groups of genes are coexpressed in these enzyme families.
Young et al (39) detail the differential effects of HDACi on the TIMP1 gene dependent on the stimulus used to induce the gene. HDACi enhance PMA-induced TIMP1 expression but repress TGFβ-induced TIMP1 expression. Interestingly, the dose-response curves for these two effects are different with e.g. >500ng/ml TSA required for the maximal enhancement of PMA-stimulated TIMP1 but only 5ng/ml TSA required for the repression of TGFβ-induced TIMP1. This strongly suggests that different HDACs are the target of HDACi in each case, and this is reinforced by the fact that valproic acid also enhances PMA-induced TIMP1, but does not block TGFβ-induced TIMP1. Furthermore, the effect of HDACi on the endogenous TIMP1 gene can be reiterated at the level of transient transfection of promoter-reporter constructs. This perhaps suggests that their effects are more likely mediated by acetylation of signaling molecules or transcription factors rather than histones.
Transcription factor and signaling pathway acetylation and MMP expression
At the simplest level, acetylation of histones at a gene promoter may increase access to cis-acting sequences by their cognate transcription factors.
However, acetylation and deacetylation of signaling pathway components and transcription factors themselves makes the situation complex (Figure 2 ). This complexity is undoubtedly increased by cell specific differences in some of these events.
AP-1
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STATs
A recent paper suggests that Stats undergo acetylation at Lys 685 and that this is essential for their dimerisation and nuclear translocation (12) . In this case, the action of HDACi would increase acetylation and therefore potentiate Stat signaling. Whilst there are instances of this in the literature (e.g. the IL-4 induction of the 15-lipoxygenase-1 gene, (42) , more recent data appear to show the opposite effect in the majority of cases. Thus HDACi have revealed an essential role for HDACs in the transcription of interferon-responsive genes (43-47) since such inhibitors repress IFN-stimulated gene expression.
NFκB
Several MMP genes respond to proinflammtory stimuli, at least in part, via the NFκB pathway (e.g. MMP1, MMP3, MMP9, MMP13 (48) . Acetylation can impact upon this signaling pathway at a number of levels. Firstly, NFκB interacts with a number of HATs (including CBP, p300, P/CAF) and HDACs to impact upon gene expression. More specifically, HDACi such as TSA delay postinduction repression of NFκB via prolonged activity of IKK and therefore persistent degradation of IκBα and delayed build up of cytoplasmic IκBα after an inflammatory stimulus. The mechanism of this enhanced IKK activity is unknown (14). Further, both p50 and p65, the most common components of the NFκB dimer can be acetylated at multiple lysine residues. p50 acetylation increases DNA-binding affinity and this correlates with induction of genes such as COX2 and iNOS (14). There are opposing views of the outcome of p65 acetylation. Kiernan et al. (49) show that p65 acetylation reduces DNA-binding affinity and enhances NFκB removal from the nucleus by IκBα and therefore abrogating NFκB action. Chen et al. (50, 51) show that p65 acetylation diminishes binding to IκBα, allowing increased nuclear translocation of NFκB and potentiation of signaling. They further show that HDAC3 deacetylates p65 to abrogate signaling and this fits with the ability of HDACi such as TSA to potentiate or prolong NFκB signaling induced by TNFα.
Smad7
Smad 7 can be acetylated on two specific Lys residues by p300 (52) . This protects Smad 7 against ubiquitination and proteosomal degradation and therefore abrogates TGFβ signaling. Smad 7 also associates with several HDACs, and at least HDAC1 deacetylates and destabilizes Smad 7 potentially to enhance TGFβ signaling (53).
Other
A number of other transcription factors relevant to MMP and TIMP gene expression are also subject to regulation at the level of acetylation, including Sp1 and Sp3 and Ets family members (54-58).
SUMMARY AND PERSPECTIVE
Changes in acetylation of histones, signalling molecules and transcription factors have profound effects upon the expression of MMP and TIMP genes. Modulation of acetylation, using histone deacetylase inhibitors therefore has the potential to modulate these effects with possible therapeutic use in pathologies where MMPs are involved.
The current literature, reviewed above, demonstrates that the effects of HDACi are often cell typeand MMP gene-specific. The exact HDAC(s) responsible for mediating the impact of a broad-spectrum HDACi on MMP gene expression is, in most cases, unknown. If inhibition of HDAC activity is to have therapeutic potential in chronic disease, this information will be crucial to the design of HDAC specific inhibitors.
Such targeted compounds may surmount problems of toxicity. Even if such optimism proves unfounded, research in this area will continue to illuminate the complexity of pathways leading to MMP gene regulation.
ACKNOWLEDGEMENT
IMC would like to acknowledge the support of the Arthritis Research Campaign, the Dunhill Medical Trust and the Norfolk and Norwich Big C Appeal. TES is funded by the Wellcome Trust and the Dunhill Medical Trust. DAY is funded by the JGWP Trust.
